The use of stem cells in biomedical research. Biotechnology Industry Organization (BIO) position statement.
On March 22, 1999, Carl B. Feldbaum, President of the Biotechnology Industry Organization (BIO), submitted comments to the National Bioethics Advisory Committee (NBAC) in response to their request for comments on stem cell research. In the statement submitted to Harold Shapiro, PhD (Chair, NBAC), Mr. Feldbaum made clear that BIO members want to ensure that the promise of new therapies and cures from research using stem cells is realized in a responsible and ethical way. In addition, all BIO members are committed to ensuring that every avenue of promising research can be responsibly explored to improve the health of individuals living with currently intractable diseases.
D035843:Biomedical Research; D001709:Biotechnology; D033041:Embryo Research; D004622:Embryo, Mammalian; D035082:Federal Government; D005380:Financing, Government; D033161:Government Regulation; D006801:Humans; D007221:Industry; D009316:National Institutes of Health (U.S.); D016134:Organizational Policy; D010330:Patents as Topic; D017149:Private Sector; D017150:Public Sector; D012109:Research Support as Topic; D013234:Stem Cells; D014481:United States